US Pharma MarketingAstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo…
AstraZeneca’s shares dropped in early trading Thursday after a heart disease treatment it is developing with Ionis Pharmaceuticals unexpectedly failed in a late-stage trial.
The UK company had aimed to show that its antisense drug ...
Source: Endpoints News